Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Technology company Cisco is among the groups involved in six virtual power purchase agreements (VPPAs) to secure energy from ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

Biogen, Cisco, IDEXX Laboratories and Waters Corporation entered into a new aggregated procurement under the Net Zero ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

The stock's fall snapped a seven-day winning streak.